Drug Trial Radar · NCT03768349
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Jan 3, 2019
Primary completion
Jul 21, 2021
Study completion Jul 21, 2021
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 7, 2018
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) or F-18 labeled PSMA 1007 in order to demonstrate their utility in detecting prostate cancer.
Conditions
- Prostate Cancer
Interventions
Ga-68 PSMA11Drug
Ga-68 PSMA11 PET/CT for detection of tumor location
F-18 PSMA 1007Drug
F-18 PSMA 1007 PET/CT for detection of tumor location
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tumor Detection on PET/CTTime frame: 12 Months post PET/CT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.